# Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial

Source: https://onco.cc/key-papers/paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014/  
OnCo record `paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 176 patients with advanced lung cancer whose disease was controlled by chemotherapy, the Cuban anti-idiotype vaccine racotumomab lengthened median survival from 6.8 to 8.2 months compared with placebo.

## Summary

Published as "A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients". Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 ganglioside found on tumour cells. Patients with stage IIIb or IV disease that was at least stable after first-line chemotherapy were randomised 1:1 to the vaccine or placebo, with overall survival as the primary endpoint.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Clinical Cancer Research
- Year: 2014
- DOI: 10.1158/1078-0432.CCR-13-1674
- Authors: Alfonso S, Valdés-Zayas A, Santiesteban ER, et al.
- Findings: Median overall survival was 8.23 months with racotumomab-alum (87 patients) and 6.80 months with placebo (89 patients) (HR 0.63, 95% CI 0.46 to 0.87, P = 0.004).; Median progression-free survival was 5.33 against 3.90 months (HR 0.73, 95% CI 0.53 to 0.99, P = 0.039).; The commonest adverse events were burning and pain at the injection site, bone pain and asthenia.
- What it means: A second Cuban therapeutic vaccine for lung cancer with randomised evidence of a modest survival gain, in a setting where few patients received further treatment at progression.
- Caveats: Only five patients per group received further anticancer therapy at progression, which differs from current practice where immunotherapy and later lines are standard.; The authors describe it as a preliminary estimate of efficacy.

## Sources

- Clin Cancer Res 2014: https://doi.org/10.1158/1078-0432.CCR-13-1674
- PubMed: https://pubmed.ncbi.nlm.nih.gov/24788102/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Racotumomab](https://onco.cc/drugs/racotumomab/)
- companies: [CIMAB](https://onco.cc/companies/cimab/)
- institutions: [Instituto Nacional de Oncología y Radiobiología (INOR)](https://onco.cc/institutions/inor-cuba/), [National Coordinating Centre of Clinical Trials, Cuba (CENCEC)](https://onco.cc/institutions/cencec-cuba/)

---
JSON: https://onco.cc/api/v1/entities/paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014.json